Your session is about to expire
← Back to Search
IL2 + Ipilimumab and Nivolumab for Melanoma
Study Summary
This trial will test whether adding Interleukin-2 to standard ipilimumab and nivolumab treatment will improve outcomes for people with advanced melanoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have serious heart or brain blood vessel problems.I haven't had a stroke or mini-stroke in the last 6 months.I am over 50 or have a history of lung issues or smoking, and need lung function tests.I had major surgery over 4 weeks ago and have fully recovered.My melanoma is confirmed to be at an advanced stage and cannot be removed by surgery.I have active cancer spread to my brain.My heart test showed low or no risk of heart issues recently.I agree to use birth control during and for 6 months after the study.I haven't had melanoma treatment or radiation in the last 3 weeks and have recovered from any past treatments.My recent scans show no active brain tumors.I have been cancer-free from any other cancer for over 2 years.My organ and bone marrow functions are normal.I have no heart conditions like heart failure or recent heart attacks.You need to have a negative pregnancy test within two weeks before joining the study.I am fully active or can carry out light work.I have a history of adrenal insufficiency.I am currently on medication for an autoimmune disorder or to suppress my immune system.You have a disease that can be measured using a specific method called RECIST version 1.1.My cancer progressed after treatment with nivolumab or pembrolizumab.I do not have any severe illnesses or social situations that would prevent me from following the study's requirements.
- Group 1: Treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedential studies involving Interleukin-2?
"Currently, 814 experiments related to Interleukin-2 are in progress. Of those studies, 89 have advanced to the third phase of trials. Although a majority of these experiments are located in Pittsburgh, Pennsylvania, there is also research being conducted at 43140 other sites worldwide."
For what medical issues is Interleukin-2 commonly prescribed?
"Interleukin-2 is a viable treatment option for those who have undergone anti-angiogenic therapy, suffer from malignant neoplasms, and experience unresectable melanoma."
Has Interleukin-2 been accepted by the FDA?
"Interlukin-2 has been rated a 2 on the Power team's scale, as there is evidence of its safety but no proof yet that it can be effective."
Are there vacancies in this medical trial for people to participate?
"Affirmative. Clinicaltrials.gov records show that this clinical trial, which was initially published on September 24 2020, is still recruiting patients. A total of 29 participants are needed from a single site to complete the study."
What is the aggregate figure of participants in this experiment?
"Affirmative, the clinicaltrial.gov portal indicates that this medical trial is actively recruiting participants. It was originally listed on September 24th 2020 and had its most recent update posted on September 30th 2022. 29 patients need to be enrolled at a single site."
Share this study with friends
Copy Link
Messenger